Hormone treatment–related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAM... by Fizazi, K., Shore, N., Smith, M., Carles, J., Lebret, T., Lietuvietis, V., Mahammedi, H., Rannikko, A., Vjaters, E., Werbrouck, P., Miskic, M., Kuss, I., Le Berre, M., Borghesi, G., Sarapohja, T., Fayerabend, S.

Get full text